Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Numinus Wellness's Sloan Ratio for the quarter that ended in May. 2025 was 0.00%.
As of May. 2025, Numinus Wellness has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Numinus Wellness (OTCPK:NUMIF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of May. 2025, Numinus Wellness has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Numinus Wellness Sloan Ratio % Related Terms
Numinus Wellness Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Numinus Wellness's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUMIF vs HLYK, SYRA, GBCS: Sloan Ratio % Comparison
For the Medical Care Facilities subindustry, Numinus Wellness's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Numinus Wellness Sloan Ratio % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Numinus Wellness's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Numinus Wellness's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Numinus Wellness's Sloan Ratio for the fiscal year that ended in Aug. 2024 is calculated as
Numinus Wellness's Net Income for the trailing twelve months (TTM) ended in May. 2025 was -2.583 (Aug. 2024 ) + -0.86 (Nov. 2024 ) + -6.41 (Feb. 2025 ) + -0.513 (May. 2025 ) = $-10.37 Mil.
Numinus Wellness's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2025 was -4.667 (Aug. 2024 ) + 0.454 (Nov. 2024 ) + -2.423 (Feb. 2025 ) + 0.281 (May. 2025 ) = $-6.36 Mil.
Numinus Wellness's Cash Flow from Investing for the trailing twelve months (TTM) ended in May. 2025 was 0.007 (Aug. 2024 ) + 0 (Nov. 2024 ) + 0.836 (Feb. 2025 ) + 0.002 (May. 2025 ) = $0.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Numinus Wellness (NUMIF) has a Sloan Ratio % of 0.00% as of May. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Numinus Wellness and its competitors.
Is Numinus Wellness' Sloan Ratio % too high?
Numinus Wellness' current Sloan Ratio % is 0.00%.
How does Numinus Wellness' Sloan Ratio % compare to HLYK and SYRA?
Numinus Wellness' Sloan Ratio % of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Healthcare Providers & Services company?
A good Sloan Ratio % depends on the Healthcare Providers & Services industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Numinus Wellness and its competitors. Numinus Wellness's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numinus Wellness stock overvalued right now?
Numinus Wellness (NUMIF) has a current Sloan Ratio % of 0.00%. The current Sloan Ratio % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Numinus Wellness (NUMIF), the current Sloan Ratio % is 0.00% as of May. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUMIF has been successfully added to your 